健康
Gong Xin's Half-Year Revenue Increased by 33 Percent, Cancer Drug Patent Approved in the US
TechNews (科技新報)
要点
- Gong Xin-KY's revenue in the first half of this year broke a record, increasing by 33 percent compared to last year.
- The company continues to receive important patent approvals for the European and US markets one after another.
- The US invention patent for the structure of four new anti-cancer chemical components was successfully registered.
- The newly developed compounds are called "benzenesulfonamide derivatives".
数据一览
%33 revenue increase4 new anti-cancer component patents
Taiwanese biotechnology company Gong Xin-KY announced that it reached record revenues in the first half of the year, with an annual increase of 33 percent. The key patent approvals obtained in the European and American markets have a significant share in this remarkable growth of the company.
Gong Xin-KY announced that it received an invention patent from the US for the structure of "benzenesulfonamide derivatives", which is a new chemical component of four different cancer drugs. This strategic step is considered an important milestone for the company to strengthen its position in global markets and reach wider audiences.
对这条新闻做出反应
询问这条新闻
回答由AI仅根据本新闻生成。
常见问题
- What is the rate of increase in Gong Xin-KY's first half-year revenue?
- The company's revenue in the first six months of this year increased by 33 percent compared to the same period last year.
- What exactly does the patent approved in the US cover?
- The patent covers the structure of four new chemical compounds called "benzenesulfonamide derivatives", developed for use in cancer treatment.
- Why does the company find these patent approvals so important?
- These patents obtained from major markets such as Europe and the US support the company's global growth strategy and increase its competitiveness in international trade.
相关新闻
健康